FDA Office of Generic Drugs
Acting Deputy Director Robert Pollock leaving the agency Jan. 1 to work for Lachman Consulting Services. He is retiring from the Public Health Service with the rank of captain after 20 years in the Commissioned Corps. In recognition of his service, he has received 10 PHS awards. Since joining FDA in 1985, Pollock has held numerous positions of increasing responsibility in the division/office of generic drugs: consumer safety officer; deputy chief and chief, Review Support Branch; chief, Program Support Staff; and director, Division of Labeling and Program Support. Prior to joining FDA, Pollock was at the Health Resources & Services Administration
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth